2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Other Pathogens, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

4621 Glycine transporter 1 inhibition reduced porphyrinogen I isomers in a cellular model of cutaneous erythropoietic porphyria (CEP)

Yi Xiang, PhD, Min Wu, PhD2, Srikanth Venkatraman, PhD3
1 Disc Medicine Inc., Watertown, Massachusetts, United States
2 Disc Medicine Inc., Watertown, Massachusetts, United States
3 Disc Medicine Inc., Watertown, Massachusetts, United States

Background: Congenital erythropoietic porphyria (CEP) is a rare inherited disorder of the heme biosynthesis pathway characterized by extreme photosensitivity, which results in bullous vesicular lesions and progressive photomutilation of sun-exposed areas. CEP is caused by biallelic mutations in the uroporphyrinogen III synthase (UROS) gene or X-linked GATA1 gene, which results in 1-5% residual UROS activity (Balwani and Desnick, Blood 2012). The UROS enzyme normally catalyzes the conversion of hydroxymethylbilane to uroporphyrinogen III during heme biosynthesis. Deficient UROS activity diverts hydroxymethylbilane to the formation of nonphysiologic type I isomers, leading to the accumulation of phototoxic porphyrins in erythroid precursors and circulating erythrocytes (Erwin and Desnick, Mol Genet Metab 2019). Because CEP results from a genetic defect in the heme biosynthetic pathway that drives excessive porphyrin accumulation, reducing substrate flux through this pathway represents a potential therapeutic strategy. By restricting glycine uptake into erythroid cells, a glycine transporter 1 (GlyT1) inhibitor may reduce glycine availability for heme synthesis, thereby reducing porphyrin production and providing a mechanistically targeted approach for the treatment of CEP.

Aim: To establish a cellular model that resembles the pathologic status of CEP and evaluate whether a GlyT1 inhibitor reduces porphyrin production.

Methods: K562 UROS-null cells were generated by CRISPR-mediated knockout (KO). Five K562 UROS-KO clones were identified, and the biallelic indels were confirmed via Sanger sequencing. Accumulation of porphyrinogen I isomers in the K562 UROS-KO clones was confirmed by increased fluorescence signal via flow cytometry with excitation wavelength of 405 nm and emission wavelength of 610/620 nm (Di Pierro et al, Diagnostics 2021). Since GlyT1 expression increases progressively during erythroid differentiation, K562 UROS-KO clone T2-30 was transduced with lentivirus expressing GlyT1 to establish the CEP cellular model. The overexpression of GlyT1 was confirmed by quantitative real-time PCR (qPCR). The K562 UROS-KO clone T2-30 overexpressing GlyT1 (the CEP cellular model) was treated with GlyT1 inhibitor DISC-E for 72 hours.

Results: GlyT1 inhibitor decreased cellular porphyrin by 30-40%. The followed dose titration experiment confirmed DISC-E reduced cellular porphyrin in K562 UROS-KO cells overexpressing GlyT1 in a dose-dependent manner, with the half-maximal inhibitory concentration (IC50) value of 39 nM.

Conclusions: These results demonstrate that inhibiting glycine uptake suppresses the production of nonphysiologic porphyrinogen I isomers in a cellular model of CEP. GlyT1 inhibitors such as bitopertin may have utility in controlling the accumulation of porphyrinogen I isomers and modify the development of clinical symptoms in patients with CEP.

Yi Xiang, PhD: Disc Medicine Inc - Current equity holder in publicly-traded company; Disc Medicine Inc - Stock (publicly traded); Disc Medicine Inc - Divested equity in a private or publicly-traded company in the past 24 months; Disc Medicine Inc - Current Employment